

TABLE 168: RASH TREATMENT-NAIVE WITH EMERGING TREATMENTS: RELATIVE RISKS AND RISK DIFFERENCE FOR ALL TREATMENT COMPARISONS — RANDOM EFFECTS MODEL

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SOF12 + RBV12	PR48	0.51 (0.17 to 1.31)	-8.98 (-16.31 to 5.61)
SOF24 + RBV24		0.78 (0.08 to 2.95)	-3.95 (-17.47 to 35.81)
SOF12 + LDV12		0.26 (0.14 to 0.46)	-13.48 (-17.49 to -9.08)
SOF8 + LDV8 + RBV8		0.90 (0.31 to 2.18)	-1.80 (-12.97 to 21.67)
SOF12 + LDV12 + RBV12		0.39 (0.20 to 0.74)	-11.14 (-15.92 to -4.65)
SOF24 + LDV24 + RBV24		0.49 (0.26 to 0.91)	-9.35 (-14.51 to -1.65)
T12 PR24-48 RGT q8		1.56 (1.08 to 2.21)	10.20 (1.39 to 22.19)
T12 PR24-48 RGT q12		1.47 (0.89 to 2.25)	8.61 (-2.13 to 23.00)
T12 PR48 q8		2.57 (1.34 to 3.97)	29.02 (6.47 to 50.79)
SOF12 + PR12		0.80 (0.38 to 1.57)	-3.60 (-11.91 to 10.28)
SOF12 PR24-48 RGT		1.55 (0.77 to 2.87)	10.05 (-4.47 to 31.65)
SIM12 PR24-48 RGT		1.12 (0.82 to 1.52)	2.13 (-3.42 to 9.17)
B24 PR28-48 RGT		1.11 (0.72 to 1.64)	2.06 (-5.13 to 11.66)
B44 PR48		2.75 (0.66 to 5.77)	32.33 (-6.95 to 75.52)
PR24		1.00 (0.31 to 2.46)	0.08 (-13.06 to 26.06)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SOF24 + RBV (low dose) 24		0.06 (0.01 to 0.30)	-17.05 (-21.06 to -11.97)
PAR/RIT12 + OMB12 + DAS12		0.22 (0.10 to 0.50)	-14.08 (-18.26 to -8.90)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.73 (0.39 to 1.31)	-4.90 (-11.80 to 5.43)
DCV24 + ASU24		0.13 (0.05 to 0.32)	-15.84 (-19.75 to -11.65)
DCV12 + SOF12		0.40 (0.05 to 1.64)	-10.88 (-18.93 to 11.66)
GRZ12 + ELB12 + RBV12		0.53 (0.17 to 1.69)	-8.61 (-16.75 to 11.56)
GRZ12 + ELB12 (50 mg q.d.)		0.28 (0.05 to 1.02)	-12.95 (-18.86 to 0.42)
GRZ18 + ELB18 (50 mg q.d.)		0.11 (0.00 to 1.00)	-15.96 (-20.77 to -0.09)
GRZ8 + ELB8 (50 mg q.d.) + RBV8		1.01 (0.00 to 5.70)	0.17 (-20.06 to 80.68)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.78 (0.09 to 3.64)	-3.99 (-17.24 to 46.38)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		1.93 (0.30 to 4.97)	17.37 (-12.94 to 66.60)
SOF24 + RBV24	SOF12 + RBV12	1.49 (0.18 to 8.38)	4.38 (-13.06 to 43.59)
SOF12 + LDV12		0.52 (0.21 to 1.39)	-4.35 (-17.87 to 1.42)
SOF8 + LDV8 + RBV8		1.78 (0.52 to 5.99)	6.79 (-8.47 to 28.84)
SOF12 + LDV12 + RBV12		0.77 (0.25 to 2.38)	-1.95 (-16.43 to 5.85)
SOF24 + LDV24 + RBV24		0.96 (0.34 to 3.08)	-0.33 (-14.21 to 8.57)
T12 PR24-48 RGT q8		3.08 (1.10 to 9.66)	18.89 (2.08 to 33.53)
T12 PR24-48 RGT q12		2.91 (0.97 to 9.16)	17.30 (-0.69 to 34.01)
T12 PR48 q8		4.93 (1.74 to 16.34)	37.00 (12.68 to 60.42)
SOF12 + PR12		1.59 (0.73 to 3.55)	5.03 (-5.06 to 14.35)
SOF12 PR24-48 RGT		2.98 (1.01 to 10.63)	18.37 (0.16 to 41.77)
SIM12 PR24-48 RGT		2.21 (0.81 to 6.99)	10.91 (-4.30 to 21.26)
B24 PR28-48 RGT		2.19 (0.77 to 7.15)	10.75 (-4.92 to 23.19)
B44 PR48		5.16 (0.96 to 20.74)	40.50 (-0.73 to 83.67)
PR24		1.93 (1.12 to 3.37)	8.58 (0.89 to 25.29)
SOF24 + RBV (low dose) 24		0.12 (0.01 to 0.55)	-7.78 (-21.77 to -2.00)
PAR/RIT12 + OMB12 + DAS12		0.45 (0.12 to 1.71)	-4.96 (-19.63 to 2.84)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.46 (0.50 to 4.42)	4.05 (-10.74 to 15.11)
DCV24 + ASU24		0.25 (0.06 to 1.08)	-6.74 (-21.46 to 0.34)
DCV12 + SOF12		0.77 (0.08 to 4.84)	-1.98 (-17.46 to 20.94)
GRZ12 + ELB12 + RBV12		1.02 (0.23 to 5.40)	0.21 (-15.49 to 21.79)
GRZ12 + ELB12 (50 mg q.d.)		0.56 (0.08 to 3.44)	-3.83 (-19.00 to 11.59)
GRZ18 + ELB18 (50 mg q.d.)		0.23 (0.01 to 2.61)	-6.44 (-21.72 to 9.83)
GRZ8 + ELB8 (50 mg q.d.) + RBV8		1.94 (0.00 to 20.66)	8.55 (-18.27 to 91.26)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		1.56 (0.13 to 10.23)	4.87 (-15.16 to 54.43)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		3.68 (0.47 to 17.27)	25.89 (-8.45 to 75.38)
SOF12 + LDV12	SOF24 + RBV24	0.34 (0.09 to 2.82)	-9.43 (-48.78 to 3.08)
SOF8 + LDV8 + RBV8		1.16 (0.23 to 10.23)	2.10 (-37.60 to 26.29)
SOF12 + LDV12 + RBV12		0.51 (0.12 to 4.37)	-7.00 (-46.30 to 6.44)
SOF24 + LDV24 + RBV24		0.64 (0.15 to 5.68)	-5.13 (-44.38 to 9.23)
T12 PR24-48 RGT q8		2.00 (0.49 to 18.40)	14.05 (-26.67 to 32.17)
T12 PR24-48 RGT q12		1.89 (0.46 to 17.88)	12.30 (-28.46 to 32.29)
T12 PR48 q8		3.11 (0.75 to 30.93)	30.83 (-12.55 to 60.42)
SOF12 + PR12		1.02 (0.25 to 9.29)	0.32 (-38.03 to 17.70)
SOF12 PR24-48 RGT		1.98 (0.45 to 20.10)	13.38 (-28.79 to 39.15)
SIM12 PR24-48 RGT		1.42 (0.37 to 13.43)	6.05 (-33.41 to 21.27)
B24 PR28-48 RGT		1.42 (0.35 to 13.09)	5.90 (-34.62 to 22.76)
B44 PR48		3.37 (0.53 to 38.71)	33.47 (-20.60 to 81.76)
PR24		1.32 (0.23 to 10.83)	4.03 (-35.51 to 30.93)
SOF24 + RBV (low dose) 24		0.08 (0.01 to 0.57)	-12.89 (-52.61 to -0.91)
PAR/RIT12 + OMB12 + DAS12		0.29 (0.06 to 2.87)	-10.28 (-49.75 to 3.57)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.94 (0.23 to 8.39)	-0.90 (-40.00 to 15.38)
DCV24 + ASU24		0.17 (0.03 to 1.76)	-11.93 (-51.52 to 1.39)
DCV12 + SOF12		0.51 (0.03 to 6.65)	-6.68 (-47.70 to 19.48)
GRZ12 + ELB12 + RBV12		0.69 (0.11 to 8.32)	-4.10 (-45.29 to 20.19)
GRZ12 + ELB12 (50 mg q.d.)		0.37 (0.04 to 4.98)	-8.29 (-48.25 to 9.93)
GRZ18 + ELB18 (50 mg q.d.)		0.16 (0.00 to 3.00)	-10.97 (-51.87 to 7.21)
GRZ8 + ELB8 (50 mg q.d.) + RBV8		1.29 (0.00 to 26.66)	3.26 (-42.39 to 89.86)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		1.13 (0.07 to 13.23)	1.43 (-44.11 to 50.78)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		2.46 (0.24 to 26.55)	19.75 (-30.89 to 72.74)
SOF8 + LDV8 + RBV8	SOF12 + LDV12	3.41 (1.44 to 7.83)	11.57 (1.91 to 34.25)
SOF12 + LDV12 + RBV12		1.49 (0.75 to 2.87)	2.26 (-1.51 to 7.97)
SOF24 + LDV24 + RBV24		1.88 (0.97 to 3.55)	4.07 (-0.16 to 10.78)
T12 PR24-48 RGT q8		5.99 (3.04 to 11.82)	23.64 (13.84 to 36.42)
T12 PR24-48 RGT q12		5.64 (2.63 to 11.70)	22.06 (10.38 to 37.26)
T12 PR48 q8		9.67 (4.56 to 19.93)	42.49 (20.42 to 63.74)
SOF12 + PR12		3.03 (1.84 to 5.23)	9.82 (3.50 to 21.84)
SOF12 PR24-48 RGT		5.87 (2.47 to 14.48)	23.59 (9.23 to 44.65)
SIM12 PR24-48 RGT		4.27 (2.24 to 8.32)	15.57 (8.92 to 23.60)
B24 PR28-48 RGT		4.28 (2.09 to 8.57)	15.49 (7.18 to 25.94)
B44 PR48		10.36 (2.31 to 27.71)	45.69 (7.71 to 87.74)
PR24		3.76 (1.30 to 9.40)	13.45 (1.44 to 38.69)
SOF24 + RBV (low dose) 24		0.23 (0.03 to 1.05)	-3.45 (-7.14 to 0.18)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
PAR/RIT12 + OMB12 + DAS12		0.86 (0.30 to 2.26)	-0.63 (-5.01 to 4.73)
PAR/RIT12 + OMB12 + DAS12 + RBV12		2.82 (1.48 to 5.27)	8.57 (2.73 to 18.01)
DCV24 + ASU24		0.49 (0.16 to 1.48)	-2.35 (-6.33 to 1.71)
DCV12 + SOF12		1.55 (0.18 to 6.55)	2.57 (-5.04 to 24.66)
GRZ12 + ELB12 + RBV12		2.02 (0.55 to 7.39)	4.83 (-2.93 to 24.43)
GRZ12 + ELB12 (50 mg q.d.)		1.09 (0.17 to 4.59)	0.43 (-5.53 to 14.21)
GRZ18 + ELB18 (50 mg q.d.)		0.42 (0.01 to 4.02)	-2.54 (-7.09 to 12.98)
GRZ8 + ELB8 (50 mg q.d.) + RBV8		3.80 (0.01 to 27.72)	13.57 (-6.42 to 94.27)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		3.11 (0.32 to 15.46)	9.63 (-3.85 to 59.29)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		7.53 (1.07 to 22.46)	30.98 (0.36 to 79.33)
SOF12 + LDV12 + RBV12	SOF8 + LDV8 + RBV8	0.43 (0.16 to 1.26)	-9.11 (-32.26 to 1.82)
SOF24 + LDV24 + RBV24		0.54 (0.20 to 1.58)	-7.38 (-30.27 to 4.21)
T12 PR24-48 RGT q8		1.73 (0.66 to 5.12)	11.95 (-12.91 to 28.25)
T12 PR24-48 RGT q12		1.62 (0.58 to 5.00)	10.15 (-15.33 to 28.95)
T12 PR48 q8		2.77 (1.04 to 8.66)	29.29 (1.14 to 55.64)
SOF12 + PR12		0.89 (0.35 to 2.43)	-1.77 (-23.11 to 12.33)
SOF12 PR24-48 RGT		1.72 (0.57 to 5.98)	11.39 (-14.77 to 36.48)
SIM12 PR24-48 RGT		1.24 (0.48 to 3.73)	3.80 (-20.12 to 17.31)
B24 PR28-48 RGT		1.23 (0.47 to 3.76)	3.73 (-20.38 to 18.84)
B44 PR48		2.94 (0.59 to 11.10)	32.43 (-11.71 to 78.18)
PR24		1.10 (0.30 to 3.94)	1.58 (-22.27 to 27.54)
SOF24 + RBV (low dose) 24		0.07 (0.01 to 0.38)	-15.06 (-38.43 to -4.23)
PAR/RIT12 + OMB12 + DAS12		0.25 (0.07 to 0.90)	-12.25 (-36.06 to -0.59)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.82 (0.30 to 2.37)	-2.83 (-26.05 to 10.13)
DCV24 + ASU24		0.14 (0.04 to 0.58)	-13.92 (-37.73 to -2.72)
DCV12 + SOF12		0.45 (0.05 to 2.45)	-8.34 (-32.75 to 13.89)
GRZ12 + ELB12 + RBV12		0.59 (0.14 to 2.77)	-6.35 (-31.54 to 15.18)
GRZ12 + ELB12 (50 mg q.d.)		0.31 (0.05 to 1.66)	-10.57 (-34.72 to 5.83)
GRZ18 + ELB18 (50 mg q.d.)		0.12 (0.00 to 1.32)	-13.20 (-37.07 to 3.15)
GRZ8 + ELB8 (50 mg q.d.) + RBV8		1.11 (0.00 to 10.63)	1.69 (-32.02 to 85.61)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.91 (0.08 to 5.50)	-1.36 (-30.30 to 48.62)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		2.17 (0.29 to 8.90)	18.61 (-20.45 to 69.54)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SOF24 + LDV24 + RBV24	SOF12 + LDV12 + RBV12	1.26 (0.66 to 2.41)	1.80 (-3.59 to 7.81)
T12 PR24-48 RGT q8		4.02 (1.94 to 8.47)	21.19 (10.44 to 34.17)
T12 PR24-48 RGT q12		3.77 (1.70 to 8.27)	19.72 (7.31 to 35.01)
T12 PR48 q8		6.56 (2.75 to 14.28)	40.09 (17.53 to 61.91)
SOF12 + PR12		2.06 (0.91 to 4.70)	7.41 (-0.79 to 20.45)
SOF12 PR24-48 RGT		3.95 (1.63 to 10.44)	20.97 (6.18 to 42.55)
SIM12 PR24-48 RGT		2.89 (1.41 to 5.96)	13.24 (4.92 to 21.64)
B24 PR28-48 RGT		2.87 (1.31 to 6.15)	13.07 (3.51 to 23.96)
B44 PR48		6.95 (1.52 to 20.45)	43.29 (4.81 to 85.44)
PR24		2.52 (0.76 to 7.39)	10.94 (-2.15 to 36.74)
SOF24 + RBV (low dose) 24		0.15 (0.02 to 0.72)	-5.71 (-12.04 to -1.50)
PAR/RIT12 + OMB12 + DAS12		0.58 (0.20 to 1.64)	-2.90 (-9.79 to 3.10)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.91 (0.84 to 4.24)	6.36 (-1.80 to 16.30)
DCV24 + ASU24		0.34 (0.10 to 1.04)	-4.56 (-11.35 to 0.20)
DCV12 + SOF12		1.04 (0.11 to 4.57)	0.24 (-9.49 to 21.99)
GRZ12 + ELB12 + RBV12		1.36 (0.35 to 5.28)	2.44 (-7.21 to 22.45)
GRZ12 + ELB12 (50 mg q.d.)		0.73 (0.11 to 3.33)	-1.82 (-10.01 to 12.22)
GRZ18 + ELB18 (50 mg q.d.)		0.29 (0.01 to 3.08)	-4.59 (-12.21 to 11.28)
GRZ8 + ELB8 (50 mg q.d.) + RBV8		2.59 (0.01 to 19.49)	11.16 (-10.29 to 92.12)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		2.06 (0.20 to 11.31)	7.28 (-7.80 to 57.15)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		4.96 (0.67 to 16.73)	28.37 (-3.09 to 77.40)
T12 PR24-48 RGT q8	SOF24 + LDV24 + RBV24	3.19 (1.58 to 6.59)	19.37 (8.15 to 32.60)
T12 PR24-48 RGT q12		3.00 (1.38 to 6.50)	17.76 (4.95 to 33.26)
T12 PR48 q8		5.18 (2.29 to 11.18)	38.17 (15.71 to 59.84)
SOF12 + PR12		1.63 (0.71 to 3.59)	5.60 (-3.49 to 18.69)
SOF12 PR24-48 RGT		3.15 (1.26 to 7.78)	19.28 (3.27 to 41.01)
SIM12 PR24-48 RGT		2.28 (1.14 to 4.62)	11.41 (2.14 to 20.05)
B24 PR28-48 RGT		2.28 (1.08 to 4.78)	11.30 (1.10 to 22.10)
B44 PR48		5.46 (1.20 to 15.44)	41.39 (2.39 to 83.81)
PR24		2.04 (0.60 to 5.73)	9.22 (-4.66 to 34.72)
SOF24 + RBV (low dose) 24		0.12 (0.01 to 0.60)	-7.55 (-15.19 to -2.62)
PAR/RIT12 + OMB12 + DAS12		0.46 (0.16 to 1.28)	-4.73 (-12.72 to 1.68)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.52 (0.66 to 3.28)	4.50 (-4.45 to 14.78)
DCV24 + ASU24		0.27 (0.08 to 0.82)	-6.45 (-14.26 to -1.03)
DCV12 + SOF12		0.82 (0.09 to 3.68)	-1.55 (-11.94 to 20.40)
GRZ12 + ELB12 + RBV12		1.09 (0.29 to 4.02)	0.80 (-9.92 to 20.54)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
GRZ12 + ELB12 (50 mg q.d.)		0.58 (0.09 to 2.59)	-3.60 (-12.90 to 10.62)
GRZ18 + ELB18 (50 mg q.d.)		0.22 (0.01 to 2.22)	-6.38 (-14.71 to 9.25)
GRZ8 + ELB8 (50 mg q.d.) + RBV8		2.04 (0.01 to 15.05)	9.27 (-12.92 to 90.46)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		1.62 (0.17 to 8.12)	5.43 (-9.97 to 54.98)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		4.00 (0.53 to 12.63)	26.69 (-5.29 to 75.57)
T12 PR24-48 RGT q12	T12 PR24-48 RGT q8	0.94 (0.68 to 1.23)	-1.61 (-9.48 to 6.62)
T12 PR48 q8		1.64 (0.82 to 2.84)	18.30 (-6.25 to 42.05)
SOF12 + PR12		0.51 (0.23 to 1.11)	-13.81 (-28.15 to 2.54)
SOF12 PR24-48 RGT		0.99 (0.47 to 2.02)	-0.15 (-19.15 to 23.08)
SIM12 PR24-48 RGT		0.72 (0.45 to 1.15)	-8.10 (-21.07 to 3.03)
B24 PR28-48 RGT		0.71 (0.41 to 1.21)	-8.08 (-22.19 to 4.73)
B44 PR48		1.76 (0.42 to 4.14)	21.91 (-19.98 to 68.20)
PR24		0.64 (0.19 to 1.69)	-10.10 (-28.58 to 17.08)
SOF24 + RBV (low dose) 24		0.04 (0.00 to 0.20)	-27.14 (-40.10 to -17.00)
PAR/RIT12 + OMB12 + DAS12		0.14 (0.07 to 0.28)	-24.24 (-34.80 to -16.01)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.47 (0.23 to 0.94)	-15.00 (-29.13 to -1.37)
DCV24 + ASU24		0.08 (0.03 to 0.22)	-25.95 (-38.91 to -16.24)
DCV12 + SOF12		0.26 (0.03 to 1.12)	-20.64 (-36.00 to 2.99)
GRZ12 + ELB12 + RBV12		0.34 (0.10 to 1.14)	-18.48 (-33.63 to 3.34)
GRZ12 + ELB12 (50 mg q.d.)		0.18 (0.03 to 0.72)	-22.77 (-36.65 to -6.47)
GRZ18 + ELB18 (50 mg q.d.)		0.07 (0.00 to 0.69)	-25.60 (-39.14 to -7.66)
GRZ8 + ELB8 (50 mg q.d.) + RBV8		0.64 (0.00 to 4.04)	-10.01 (-36.11 to 72.30)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.50 (0.06 to 2.40)	-13.81 (-32.50 to 36.69)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		1.23 (0.18 to 3.40)	6.61 (-25.35 to 56.95)
T12 PR48 q8	T12 PR24-48 RGT q12	1.73 (0.83 to 3.33)	19.84 (-5.73 to 44.29)
SOF12 + PR12		0.55 (0.23 to 1.29)	-12.05 (-28.64 to 5.63)
SOF12 PR24-48 RGT		1.06 (0.48 to 2.35)	1.51 (-18.94 to 25.56)
SIM12 PR24-48 RGT		0.76 (0.45 to 1.36)	-6.54 (-21.55 to 6.28)
B24 PR28-48 RGT		0.76 (0.41 to 1.44)	-6.51 (-22.43 to 8.08)
B44 PR48		1.85 (0.44 to 4.74)	23.22 (-18.81 to 70.14)
PR24		0.68 (0.20 to 1.93)	-8.40 (-28.73 to 19.57)
SOF24 + RBV (low dose) 24		0.04 (0.00 to 0.22)	-25.60 (-40.75 to -13.67)
PAR/RIT12 + OMB12 + DAS12		0.15 (0.07 to 0.32)	-22.63 (-36.13 to -12.20)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.50 (0.23 to 1.09)	-13.33 (-29.58 to 1.71)
DCV24 + ASU24		0.09 (0.03 to 0.25)	-24.41 (-39.58 to -12.84)
DCV12 + SOF12		0.27 (0.03 to 1.25)	-18.87 (-36.35 to 5.27)
GRZ12 + ELB12 + RBV12		0.36 (0.10 to 1.26)	-16.71 (-33.96 to 5.50)
GRZ12 + ELB12 (50 mg q.d.)		0.20 (0.03 to 0.79)	-20.97 (-37.25 to -4.12)
GRZ18 + ELB18 (50 mg q.d.)		0.07 (0.00 to 0.77)	-23.92 (-40.01 to -4.89)
GRZ8 + ELB8 (50 mg q.d.) + RBV8		0.69 (0.00 to 4.60)	-8.21 (-35.91 to 74.72)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.54 (0.06 to 2.62)	-11.85 (-32.77 to 38.83)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		1.31 (0.19 to 3.87)	8.26 (-24.90 to 58.94)
SOF12 + PR12	T12 PR48 q8	0.32 (0.13 to 0.72)	-31.82 (-55.55 to -8.57)
SOF12 PR24-48 RGT		0.61 (0.27 to 1.47)	-18.29 (-46.41 to 13.47)
SIM12 PR24-48 RGT		0.44 (0.25 to 0.89)	-26.72 (-49.87 to -2.89)
B24 PR28-48 RGT		0.43 (0.24 to 0.89)	-26.70 (-49.57 to -2.96)
B44 PR48		1.07 (0.26 to 2.80)	3.12 (-42.82 to 56.18)
PR24		0.40 (0.12 to 1.10)	-27.50 (-54.84 to 3.58)
SOF24 + RBV (low dose) 24		0.02 (0.00 to 0.13)	-46.01 (-67.56 to -23.39)
PAR/RIT12 + OMB12 + DAS12		0.09 (0.03 to 0.24)	-42.91 (-64.61 to -20.46)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.29 (0.16 to 0.54)	-33.25 (-53.89 to -13.26)
DCV24 + ASU24		0.05 (0.02 to 0.15)	-44.81 (-66.14 to -22.40)
DCV12 + SOF12		0.16 (0.03 to 0.53)	-37.84 (-57.95 to -18.65)
GRZ12 + ELB12 + RBV12		0.21 (0.06 to 0.72)	-36.31 (-60.57 to -8.64)
GRZ12 + ELB12 (50 mg q.d.)		0.11 (0.02 to 0.49)	-40.95 (-63.91 to -15.38)
GRZ18 + ELB18 (50 mg q.d.)		0.04 (0.00 to 0.44)	-44.12 (-66.02 to -18.21)
GRZ8 + ELB8 (50 mg q.d.) + RBV8		0.40 (0.00 to 2.78)	-25.33 (-62.67 to 59.44)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.31 (0.03 to 1.65)	-30.87 (-59.01 to 23.43)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		0.76 (0.10 to 2.33)	-11.07 (-52.06 to 42.89)
SOF12 PR24-48 RGT	SOF12 + PR12	1.93 (0.76 to 5.41)	13.45 (-5.52 to 36.62)
SIM12 PR24-48 RGT		1.40 (0.66 to 3.12)	5.78 (-9.36 to 16.53)
B24 PR28-48 RGT		1.39 (0.63 to 3.18)	5.56 (-9.61 to 18.32)
B44 PR48		3.33 (0.72 to 10.13)	35.25 (-5.80 to 80.62)
PR24		1.22 (0.49 to 2.84)	3.19 (-8.68 to 24.78)
SOF24 + RBV (low dose) 24		0.08 (0.01 to 0.33)	-13.42 (-26.57 to -5.68)
PAR/RIT12 + OMB12 + DAS12		0.28 (0.09 to 0.83)	-10.40 (-24.66 to -1.39)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.92 (0.41 to 2.08)	-1.19 (-14.61 to 9.68)
DCV24 + ASU24		0.16 (0.05 to 0.53)	-12.28 (-26.31 to -3.82)
DCV12 + SOF12		0.50 (0.06 to 2.35)	-7.02 (-22.66 to 15.37)
GRZ12 + ELB12 + RBV12		0.67 (0.16 to 2.65)	-4.72 (-20.94 to 16.59)
GRZ12 + ELB12 (50 mg q.d.)		0.36 (0.05 to 1.69)	-9.02 (-24.94 to 6.70)
GRZ18 + ELB18 (50 mg q.d.)		0.14 (0.00 to 1.38)	-11.56 (-26.78 to 4.09)
GRZ8 + ELB8 (50 mg q.d.) + RBV8		1.25 (0.00 to 10.11)	3.55 (-23.22 to 86.22)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		1.01 (0.10 to 5.09)	0.16 (-20.78 to 49.14)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		2.40 (0.34 to 8.29)	20.74 (-13.33 to 69.78)
SIM12 PR24-48 RGT	SOF12 PR24-48 RGT	0.72 (0.37 to 1.52)	-8.04 (-29.90 to 8.33)
B24 PR28-48 RGT		0.71 (0.34 to 1.57)	-8.07 (-30.50 to 9.49)
B44 PR48		1.74 (0.40 to 5.06)	21.43 (-24.40 to 70.43)
PR24		0.65 (0.17 to 1.92)	-9.59 (-36.34 to 18.55)
SOF24 + RBV (low dose) 24		0.04 (0.00 to 0.20)	-27.10 (-47.73 to -13.10)
PAR/RIT12 + OMB12 + DAS12		0.14 (0.05 to 0.41)	-24.24 (-44.98 to -9.41)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.47 (0.19 to 1.15)	-14.75 (-37.33 to 2.54)
DCV24 + ASU24		0.08 (0.03 to 0.26)	-25.99 (-46.39 to -11.80)
DCV12 + SOF12		0.25 (0.03 to 1.19)	-20.34 (-43.41 to 4.22)
GRZ12 + ELB12 + RBV12		0.34 (0.09 to 1.29)	-18.52 (-40.23 to 5.99)
GRZ12 + ELB12 (50 mg q.d.)		0.18 (0.03 to 0.82)	-22.72 (-44.17 to -3.63)
GRZ18 + ELB18 (50 mg q.d.)		0.07 (0.00 to 0.69)	-25.15 (-46.19 to -6.72)
GRZ8 + ELB8 (50 mg q.d.) + RBV8		0.65 (0.00 to 4.70)	-9.38 (-42.25 to 74.63)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.51 (0.05 to 2.65)	-13.32 (-39.40 to 37.03)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		1.24 (0.17 to 4.01)	6.72 (-30.78 to 58.28)
B24 PR28-48 RGT	SIM12 PR24-48 RGT	1.00 (0.59 to 1.63)	-0.08 (-9.93 to 10.97)
B44 PR48		2.47 (0.58 to 5.47)	30.17 (-10.23 to 73.86)
PR24		0.90 (0.27 to 2.35)	-1.98 (-17.14 to 24.63)
SOF24 + RBV (low dose) 24		0.05 (0.01 to 0.28)	-19.10 (-27.05 to -11.92)
PAR/RIT12 + OMB12 + DAS12		0.20 (0.08 to 0.47)	-16.12 (-24.10 to -8.94)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.66 (0.32 to 1.27)	-6.97 (-16.82 to 4.71)
DCV24 + ASU24		0.12 (0.05 to 0.27)	-17.94 (-24.99 to -12.27)
DCV12 + SOF12		0.36 (0.04 to 1.54)	-12.89 (-23.57 to 10.27)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
GRZ12 + ELB12 + RBV12		0.47 (0.14 to 1.56)	-10.63 (-21.46 to 10.07)
GRZ12 + ELB12 (50 mg q.d.)		0.25 (0.05 to 0.97)	-15.01 (-24.02 to -0.48)
GRZ18 + ELB18 (50 mg q.d.)		0.10 (0.00 to 0.93)	-17.72 (-26.41 to -1.33)
GRZ8 + ELB8 (50 mg q.d.) + RBV8		0.90 (0.00 to 5.47)	-1.92 (-24.50 to 79.14)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.70 (0.08 to 3.27)	-6.00 (-21.56 to 43.67)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		1.71 (0.26 to 4.66)	14.87 (-15.94 to 64.90)
B44 PR48	B24 PR28-48 RGT	2.46 (0.57 to 5.90)	30.07 (-10.37 to 74.24)
PR24		0.90 (0.26 to 2.46)	-1.94 (-18.91 to 25.11)
SOF24 + RBV (low dose) 24		0.05 (0.01 to 0.28)	-19.00 (-29.45 to -10.59)
PAR/RIT12 + OMB12 + DAS12		0.20 (0.08 to 0.50)	-16.05 (-26.49 to -7.40)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.66 (0.31 to 1.36)	-6.70 (-18.91 to 5.48)
DCV24 + ASU24		0.12 (0.04 to 0.32)	-17.81 (-28.14 to -9.76)
DCV12 + SOF12		0.36 (0.04 to 1.59)	-12.61 (-25.88 to 10.30)
GRZ12 + ELB12 + RBV12		0.48 (0.14 to 1.62)	-10.45 (-23.43 to 10.28)
GRZ12 + ELB12 (50 mg q.d.)		0.26 (0.05 to 1.03)	-14.78 (-26.38 to 0.57)
GRZ18 + ELB18 (50 mg q.d.)		0.10 (0.00 to 0.95)	-17.49 (-28.78 to -0.81)
GRZ8 + ELB8 (50 mg q.d.) + RBV8		0.90 (0.00 to 5.82)	-1.99 (-26.02 to 80.08)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.71 (0.08 to 3.37)	-5.79 (-22.89 to 43.61)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		1.73 (0.26 to 4.93)	15.04 (-16.36 to 64.83)
PR24	B44 PR48	0.37 (0.09 to 1.95)	-31.45 (-76.10 to 16.07)
SOF24 + RBV (low dose) 24		0.02 (0.00 to 0.16)	-49.21 (-90.60 to -11.95)
PAR/RIT12 + OMB12 + DAS12		0.08 (0.02 to 0.41)	-46.22 (-88.32 to -8.32)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.27 (0.10 to 1.24)	-36.97 (-79.87 to 3.43)
DCV24 + ASU24		0.05 (0.01 to 0.27)	-48.15 (-89.81 to -10.18)
DCV12 + SOF12		0.15 (0.02 to 1.14)	-41.90 (-84.83 to 2.42)
GRZ12 + ELB12 + RBV12		0.20 (0.05 to 1.09)	-39.67 (-82.83 to 1.52)
GRZ12 + ELB12 (50 mg q.d.)		0.11 (0.02 to 0.67)	-44.30 (-88.21 to -5.31)
GRZ18 + ELB18 (50 mg q.d.)		0.04 (0.00 to 0.55)	-47.21 (-90.77 to -7.45)
GRZ8 + ELB8 (50 mg q.d.) + RBV8		0.39 (0.00 to 4.30)	-24.04 (-84.76 to 68.29)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.32 (0.03 to 2.04)	-32.29 (-83.09 to 22.68)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		0.75 (0.09 to 3.51)	-12.22 (-69.92 to 46.34)
SOF24 + RBV (low dose) 24	PR24	0.06 (0.01 to 0.32)	-16.97 (-42.44 to -4.55)
PAR/RIT12 + OMB12 + DAS12		0.23 (0.06 to 0.92)	-14.06 (-40.05 to -0.54)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.75 (0.26 to 2.41)	-4.66 (-30.00 to 10.27)
DCV24 + ASU24		0.13 (0.03 to 0.59)	-15.82 (-42.06 to -2.62)
DCV12 + SOF12		0.40 (0.04 to 2.55)	-10.06 (-37.03 to 14.64)
GRZ12 + ELB12 + RBV12		0.52 (0.12 to 2.79)	-8.37 (-35.74 to 15.24)
GRZ12 + ELB12 (50 mg q.d.)		0.29 (0.04 to 1.84)	-12.64 (-39.64 to 6.83)
GRZ18 + ELB18 (50 mg q.d.)		0.12 (0.00 to 1.44)	-15.28 (-41.77 to 3.93)
GRZ8 + ELB8 (50 mg q.d.) + RBV8		1.01 (0.00 to 10.84)	0.17 (-36.50 to 85.50)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.82 (0.06 to 5.36)	-2.86 (-34.31 to 46.56)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		1.90 (0.23 to 9.14)	16.53 (-25.53 to 68.34)
PAR/RIT12 + OMB12 + DAS12	SOF24 + RBV (low dose) 24	3.80 (0.58 to 34.03)	2.86 (-1.96 to 8.18)
PAR/RIT12 + OMB12 + DAS12 + RBV12		12.49 (2.27 to 113.30)	12.08 (5.05 to 22.35)
DCV24 + ASU24		2.26 (0.33 to 20.67)	1.20 (-3.34 to 4.85)
DCV12 + SOF12		6.54 (0.52 to 75.97)	5.88 (-1.36 to 28.43)
GRZ12 + ELB12 + RBV12		9.02 (1.14 to 97.60)	8.33 (0.54 to 27.63)
GRZ12 + ELB12 (50 mg q.d.)		5.02 (0.44 to 52.66)	3.91 (-1.77 to 17.62)
GRZ18 + ELB18 (50 mg q.d.)		1.99 (0.04 to 34.36)	0.85 (-3.83 to 16.91)
GRZ8 + ELB8 (50 mg q.d.) + RBV8		16.11 (0.04 to 342.20)	17.03 (-2.56 to 97.84)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		14.06 (0.86 to 145.90)	13.25 (-0.38 to 62.93)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		32.21 (2.49 to 261.20)	34.43 (3.62 to 83.05)
PAR/RIT12 + OMB12 + DAS12 + RBV12	PAR/RIT12 + OMB12 + DAS12	3.27 (1.20 to 9.29)	9.19 (1.45 to 19.67)
DCV24 + ASU24		0.58 (0.17 to 2.02)	-1.65 (-6.97 to 2.50)
DCV12 + SOF12		1.77 (0.19 to 9.57)	3.04 (-5.35 to 25.86)
GRZ12 + ELB12 + RBV12		2.36 (0.57 to 10.06)	5.35 (-3.02 to 24.86)
GRZ12 + ELB12 (50 mg q.d.)		1.29 (0.20 to 6.05)	1.10 (-5.70 to 14.46)
GRZ18 + ELB18 (50 mg q.d.)		0.48 (0.02 to 5.93)	-1.91 (-7.80 to 14.52)
GRZ8 + ELB8 (50 mg q.d.) + RBV8		4.41 (0.01 to 38.37)	14.13 (-6.39 to 95.04)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		3.52 (0.33 to 21.16)	10.09 (-3.53 to 60.25)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		8.47 (1.18 to 33.26)	31.31 (0.91 to 80.05)
DCV24 + ASU24	PAR/RIT12 + OMB12 + DAS12 + RBV12	0.18 (0.06 to 0.52)	-10.93 (-21.27 to -3.97)
DCV12 + SOF12		0.55 (0.07 to 2.23)	-5.72 (-17.09 to 14.78)
GRZ12 + ELB12 + RBV12		0.71 (0.20 to 2.61)	-3.83 (-16.33 to 16.78)
GRZ12 + ELB12 (50 mg q.d.)		0.39 (0.06 to 1.63)	-7.93 (-19.43 to 6.67)
GRZ18 + ELB18 (50 mg q.d.)		0.15 (0.00 to 1.54)	-10.67 (-21.54 to 5.52)
GRZ8 + ELB8 (50 mg q.d.) + RBV8		1.38 (0.00 to 9.87)	4.91 (-19.36 to 86.56)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		1.08 (0.10 to 5.77)	0.97 (-16.65 to 51.21)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		2.61 (0.35 to 8.56)	21.75 (-10.04 to 71.91)
DCV12 + SOF12	DCV24 + ASU24	3.05 (0.34 to 17.51)	4.75 (-2.45 to 27.17)
GRZ12 + ELB12 + RBV12		4.12 (0.89 to 18.95)	7.13 (-0.47 to 26.29)
GRZ12 + ELB12 (50 mg q.d.)		2.22 (0.33 to 11.47)	2.72 (-2.71 to 16.36)
GRZ18 + ELB18 (50 mg q.d.)		0.83 (0.03 to 9.61)	-0.38 (-4.60 to 15.46)
GRZ8 + ELB8 (50 mg q.d.) + RBV8		7.60 (0.02 to 70.79)	15.88 (-3.74 to 96.54)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		6.19 (0.58 to 37.47)	11.96 (-1.36 to 61.44)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		14.78 (1.93 to 60.50)	33.25 (2.65 to 81.64)
GRZ12 + ELB12 + RBV12	DCV12 + SOF12	1.38 (0.20 to 12.58)	2.48 (-21.09 to 22.22)
GRZ12 + ELB12 (50 mg q.d.)		0.72 (0.07 to 9.76)	-1.77 (-24.97 to 13.75)
GRZ18 + ELB18 (50 mg q.d.)		0.29 (0.01 to 5.52)	-4.40 (-26.89 to 12.58)
GRZ8 + ELB8 (50 mg q.d.) + RBV8		2.47 (0.01 to 50.87)	9.94 (-21.81 to 93.31)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		2.07 (0.14 to 25.21)	6.63 (-19.20 to 57.67)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		4.89 (0.42 to 51.20)	27.14 (-10.72 to 76.99)
GRZ12 + ELB12 (50 mg q.d.)	GRZ12 + ELB12 + RBV12	0.55 (0.11 to 1.88)	-4.00 (-19.25 to 5.80)
GRZ18 + ELB18 (50 mg q.d.)		0.20 (0.01 to 2.32)	-6.89 (-25.50 to 8.46)
GRZ8 + ELB8 (50 mg q.d.) + RBV8		1.86 (0.00 to 19.79)	8.19 (-21.43 to 90.82)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		1.48 (0.17 to 8.86)	4.58 (-14.10 to 52.79)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		3.52 (0.53 to 13.76)	24.80 (-6.17 to 72.57)
GRZ18 + ELB18 (50 mg q.d.)	GRZ12 + ELB12 (50 mg q.d.)	0.38 (0.02 to 4.24)	-2.92 (-14.75 to 10.59)
GRZ8 + ELB8 (50 mg q.d.) + RBV8		3.41 (0.01 to 49.94)	12.50 (-13.12 to 94.33)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		2.66 (0.49 to 16.53)	8.44 (-2.99 to 55.77)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		6.19 (1.61 to 30.13)	29.53 (2.56 to 75.01)
GRZ8 + ELB8 (50 mg q.d.) + RBV8	GRZ18 + ELB18 (50 mg q.d.)	8.22 (0.02 to 587.70)	14.96 (-10.76 to 97.07)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		7.10 (0.80 to 150.20)	10.99 (-1.18 to 56.29)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		15.92 (2.26 to 379.00)	32.14 (4.17 to 78.15)
GRZ12 + ELB12 (50 mg q.d.) + RBV12	GRZ8 + ELB8 (50 mg q.d.) + RBV8	0.82 (0.04 to 372.80)	-2.56 (-89.61 to 51.44)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		1.84 (0.12 to 794.50)	11.49 (-78.35 to 75.57)
GRZ18 + ELB18 (50 mg q.d.) + RBV18	GRZ12 + ELB12 (50 mg q.d.) + RBV12	2.23 (0.82 to 10.03)	17.92 (-4.44 to 53.99)
Random effect model	Residual deviance	70.62 vs. 73 data points	
	Deviance information criteria	407.53	
Fixed effect model	Residual deviance	71.8 vs. 73 data points	
	Deviance information criteria	407.329	

ASU = asunaprevir; B = boceprevir; BEC = beclabuvir; Crl = credible interval; DAS = dasabuvir; DCV = daclatasvir; ELB = elbasvir; GRZ = grazoprevir; LDV = ledipasvir; OMB = ombitasvir; PAR = paritaprevir; PR = pegylated interferon plus ribavirin; q8 = every 8 hours; q12 = every 12 hours; q.d. = once daily; RBV = ribavirin; RD = risk difference; RGT = response-guided therapy; RIT = ritonavir; RR = relative risk; SIM = simeprevir; SOF = sofosbuvir; T = telaprevir; vs. = versus.

Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.